Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: The SPARE-1 study

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 303-310

  Saraux, Alain ^a,i   Rouanet, Stéphanie ^b   Flipo, René Marc ^c   Poncet, Jean Cyril ^d   Fardellone, Patrice ^e   Hilliquin, Pascal ^f   Idier, Isabelle ^g   Cantagrel, Alain ^h  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b EXYSTAT SAS   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Private office   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^g Chugai   (France)

^h CHU PURPAN   (France)

ⁱ Universite de Brest   (France)

Author keywords

Disease activity; Epidemiology; Glucocorticoids; Rheumatoid arthritis; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLUCOCORTICOID SPARING EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES;

EID: 84963791917     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. GUILLEMIN F, SARAUX A, GUGGENBUHL P et al.: Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005; 64: 1427-30
2. LEE DM, WEINBLATT ME: Rheumatoid arthritis [review]. Lancet 2001; 358: 903-11
3. SCOTT DL: Radiological progression in established rheumatoid arthritis. J Rheumatol 2004; 69 (Suppl.): 55-65
4. WELSING PM, van GESTEL AM, SWINKELS HL, KIEMENEY LA, van RIEL PL: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17
5. HOES JN, JACOBS JWG, VERSTAPPEN SMM, BIJLSMA JW, Van der HEIJDEN GJ: Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a metaanalysis. Ann Rheum Dis 2009; 68: 1833-8
6. GORTER SL, BIJLSMA JW, CUTOLO M et al.: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-4
7. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509
8. PINCUS T, SOKKA T, CASTREJóN I, CUTOLO M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013; 65: 729-36
9. AKAR S, TINAZLI M: Is attenuated COBRA treatment strategy (COBRA-light) non-inferior or not non-inferior than original COBRA strategy? Clin Exp Rheumatol 2014; 32 (Suppl. 87): S-18
10. van der GOES MC, HOES JN, CRAMER MJ et al.: Identifying factors hampering physical activity in longstanding rheumatoid arthritis: what is the role of glucocorticoid therapy? Clin Exp Rheumatol 2014; 32: 155-61
11. HETLAND ML, LINDEGAARD HM, HANSEN A et al.: Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2008; 67: 1023-6
12. NAUMANN L, HUSCHER D, DETERT J, SPENGLER M, BURMESTER GR, BUTTGEREIT F: Anti-tumour necrosis factor a therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis 2009; 68: 1934-6
13. GENOVESE MC, McKAY JD, NASONOV EL et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80
14. SMOLEN JS, BEAULIEU A, RUBBERT-ROTH A et al.: Effect of intreleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled randomised trial. Lancet 2008; 371: 987-97
15. KREMER J, Le LOëT X, HALLAND AM et al.: Safety of tocilizumab (TCZ) in combination with methotrexate (MTX): 2-year data from LITHE. Ann Rheum Dis 2010; 69 (Suppl. 3):387
16. EMERY P, KEYSTONE E, TONY HP et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008; 67: 1516-23. Erratum in: Ann Rheum Dis 2009; 68: 296
17. JONES G, SEBBA A, GU J et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96
18. BYKERK V, OSTöR A, ALVARO-GRACIA J et al.: Tocilizumab in patients with rheumatoid arthritis and an inadequate response to DMARDs and/or TNF inhibitor therapy: ACT SURE preliminary results. Ann Rheum Dis 2010; 69 (Suppl. 3): 379
19. AVORN J: In Defense of Pharmacoepidemiology-Embracing the Yin and Yang of Drug Research. N Engl J Med 2007; 357: 2219-21
20. GOSSEC L, DOUGADOS M, RINCHEVAL N et al.: Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009; 68: 1680-85
21. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45
22. BURMESTER GR, von HINüBER U, RICHTER C et al.: Tocilizumab administered in daily clinical practice-Final results of the German non-interventional study «ROUTINE». EULAR 2013, Madrid, Spain 12-15 June 2013. Abstract no. FRI0233
23. FORSBLAD-D'ELIA H, BENGTSSON K, KRISTENSEN LE, JACOBSSON LTH: Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register. Arhtritis Rheum 2012; 64 (Suppl.): S201
24. LEFFERS HC, ØSTERGAARD M, GLINTBORG B et al.: Two-year drug survival and treatment effect of abatacept and tocilizumab in the treatment of rheumatoid arthritis in routine care. Results from the nationwide Danish Danbio registry. Arhtritis Rheum 2012; 64 (Suppl.): S543
25. NISHIMOTO N, MIYASAKA N, YAMAMOTO K, KAWAI S, TAKEUCHI T, AZUMA J: Long term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68: 1580-4
26. NISHIMOTO N, ITO K, TAKAGI N: Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six trials and five longterm extensions. Mod Rheumatol 2010; 20: 222-32
27. NAUMANN L, HUSCHER D, DETERT J et al.: Anti-tumour necrosis factor a therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis 2009; 68: 1934-6
28. FORTUNET C, PERS YM, LAMBERT J et al.:. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatology (Oxford) 2015; 54: 672-7